Anaplastic Oligodendroglioma (AO) Completed Phase 2 Trials for Trametinib (DB08911)

Also known as: Anaplastic Oligodendroglioma / Anaplastic Oligodendrogliomas / Malignant oligodendroglioma / Oligodendroglioma, anaplastic (morphologic abnormality) / Oligodendroglioma malignant

IndicationStatusPhase
DBCOND0052374 (Anaplastic Oligodendroglioma (AO))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02684058
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG TumorsTreatment